Cambridge-based start-up company Bicycle Therapeutics has recently raised £40 million from a range of investors to bring its cancer drug candidates to clinical trials.
A common class of chemicals found everywhere from car exhausts, smoke, building materials and furniture to cosmetics and shampoos could increase cancer risk because of their ability to break down the repair mechanisms that prevent faults in our genes, according to a study published today in the journal Cell.
Why do we age when we get older? Epigenetics may hold the answer – but could it one day help us turn back the clock? Professor Wolf Reik from the Department of Physiology, Development and Neuroscience at the University of Cambridge and Dr Oliver Stegle from the European Bioinformatics Institute look at the ‘epigenetic clock’ in The Conversation.
Study identifies hundreds of genes that influence timing of puberty and alter risk of several cancers24 Apr 2017
The largest genomic analysis of puberty timing in men and women conducted to date has identified 389 genetic signals associated with puberty timing, four times the number that were previously known.
A genetic trawl through the DNA of almost 100,000 people, including 17,000 patients with the most common type of ovarian cancer, has identified 12 new genetic variants that increase risk of developing the disease and confirmed the association of 18 of the previously published variants.
Cambridge scientists have received two of the biggest funding grants ever awarded by Cancer Research UK, with the charity set to invest £40 million over the next five years in two ground-breaking research projects in the city.
Researchers in Cambridge are set to receive a £5m Cancer Research UK’s Catalyst Award to improve the early detection of cancers in GP surgeries. The CanTest team, led by Dr Fiona Walter from the University of Cambridge, will work with researchers in three UK sites and across the globe on a five year project that will help GPs to detect cancers in a primary care setting, enabling patients to benefit from innovative approaches and new technologies, and reducing the burden of referrals.
Cambridge scientists are set to receive a major cash injection from Cancer Research UK, which has announced plans to invest over £41 million over the next five years at the Cancer Research UK Cambridge Centre, one of the University of Cambridge’s Strategic Research Initiatives. The funding will help support ground-breaking work as part of the development of a unique chain of research hubs around the UK.
Two Cambridge institutes have today been confirmed as major research centres by biomedical research charity Wellcome, receiving continued support for a further five years. The centres will be co-funded by Cancer Research UK (CRUK) and the Medical Research Council (MRC) respectively.